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An Internet-based questionnaire study involving patients with asthma and chronic obstructive
pulmonary disease (COPD) and parents of children with asthma was conducted to evaluate
adherence to treatment, and convenience of inhalation and transdermal formulations. Valid
responses were obtained from 1470 patients. Among asthmatic patients, the percentage of
those who selected ‘‘taking as prescribed’’ was 52.7% for inhalant users and 83.2% for
transdermal users. Among patients with COPD, the corresponding values were 54.7% and
86.6%. There was a significant difference (po0.01) in treatment compliance between
inhalation and transdermal formulations in both groups. The most common reason for poor
adherence was ‘‘frequency of administration’’, and 83.2% of the patients preferred a once-
daily administration. In addition, patients who had used both types of formulations preferred
the transdermal ones. In conclusion, health care professionals should further educate their
patients about the importance of treatment with inhalants, since poor adherence to
treatment with inhalation formulations significantly hinders achievement of optimal efficacy.
In addition, transdermal tulobuterol patch, which is administered once daily as a long-acting,
b2-agonist, appeared to be useful for long-term control of both asthma and COPD.
& 2007 Published by Elsevier Ltd.Introduction
Adherence to medical treatment is an essential factor in
ensuring appropriate pharmacological efficacy. No drugsPublished by Elsevier Ltd.
395 4951;
dai.com (G. Tamura).exert maximal effects unless patients take them as
prescribed. Since bronchial asthma and COPD are chronic
diseases, continuous treatment with inhalation agents is
recommended for both of them, and numerous carefully
controlled trials have confirmed that these agents are very
effective for both pathological conditions. However, they
are unlikely to exert full effects when treatment compliance
is poor. In addition, some investigators have reported that
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Table 1 Questionnaire.
Q1. Are you taking drugs currently prescribed for
treatment of asthma/COPD as directed by your
physicians? Please provide an answer for each drug.
Asthma: DPI-LABA, MDI-SABA, DPI-CS, MDI-CS, TP-LABA
COPD: DPI-LABA, MDI-SABA, MDI-anticholinergic, TP-LABA
1. Taking as prescribed
2. Sometimes failing to take as prescribed
3. Often failing to take as prescribed
4. Always failing to take as prescribed
Q2. Which part of the treatment regimen is difficult to
follow? Please provide an answer for your each drug
(please select all that apply).
1. Method of administration
2. Frequency of administration
3. Timing of administration
4. Other ( )
Q3. Please indicate the most preferable frequency of
administration for your asthma/COPD drugs.
1. Once a day, 2. Twice a day, 3. Three times a day or
more.
Q4. Please rate the convenience of use of your drugs for
asthma/COPD using the following rank scale.
1. Difficult, 2. Slightly difficult, 3. Easy, 4. Very easy.
The following questions are for patients who use or have
used both inhaled drugs and transdermal drug.
Q5. Would you like to replace inhaled drugs with
transdermal drug?
1. Definitely yes, 2. Probably yes, 3. Unsure, 4. Probably
not, 5. Definitely not.
Q6. Would you like to replace transdermal drug with
inhaled drugs?
1. Definitely yes, 2. Probably yes, 3. Unsure, 4. Probably
not, 5. Definitely not.
G. Tamura, K. Ohta1896adherence to treatment with inhalants is poor because of
the complex procedures required to use them, as well as the
tedious, frequent dosing.1–4
Japanese guidelines, such as the ‘‘Guidelines for the
Prevention and Management of Asthma’’,5 ‘‘EBM-Based
Guidelines for Appropriate Use of Antiasthmatic Drugs’’,6
and ‘‘Guidelines for the Diagnosis and Treatment of COPD’’,7
recommend the use of tulobuterol patch (TP), a long-acting
b2-agonist (LABA). TP is the first long-acting transdermal
patch preparation of the b2-agonist tulobuterol, and is
designed to exert sustained b2-agonistic effects for 24 h
when applied once daily. Tamura et al.8 recently found in a
randomized, double-blind, double-dummy, parallel-group
multicenter trial that 4-week treatment with TP dose-
dependently improved the morning and evening peak
expiratory flow in patients with asthma who required
treatment with inhaled corticosteroids (CS) and short-acting
b2-agonists (SABA). In a multicenter, randomized, open-
label, parallel-group comparison study of COPD patients
treated with either TP or inhaled salmeterol, Fukuchi et al.9
demonstrated that TP improved St. George’s Respiratory
Questionnaire scores more effectively than inhaled salme-
terol. These findings indicated that TP is useful for the
management of stable COPD, with an efficacy equivalent or
superior to that of inhaled salmeterol.
In addition, treatment compliance was significantly
better with TP than with inhaled salmeterol in that study.
However, adherence in inhalant and patch users in clinical
practice, not in a clinical study based on a rigorous protocol,
has not been reported. Thus, this study was conducted to
clarify the adherence in clinical practice through an Internet
survey.
Subjects and methods
Participants
The participants in this survey were 2000 patients with
asthma who had been or were under treatment with dry-
powder inhaler (DPI)-LABA, metered-dose inhaler (MDI)-
SABA, DPI-CS, MDI-CS, or TP-LABA and 1000 patients with
COPD who had been or were under treatment with DPI-
LABA, MDI-SABA, MDI-anticholinergic, or TP-LABA. These
patients were randomly selected from among 10,100
patients with asthma and 1523 patients with COPD who
voluntarily accessed a health care communication website,
‘‘My Hospitals’’ (http://www.my-hospitals.net), and agreed
to answer questionnaires about their treatment. In the
present study, a questionnaire (Table 1) was sent to the
participants via E-mail. When the number of effective
responses reached the target number of 1500, which
corresponded to half the number of selected patients, the
survey was concluded. In this survey, the subjects volunta-
rily replied to the questionnaire.
Methods of administration and contents of the
questionnaire
The questionnaire survey was carried out during February
15–26, 2005. The participants were asked to answer
questions about self-management of asthma or COPD viathe My Hospitals website. Protection of privacy of the data
collected via the website was achieved by allowing access to
the site only to the participants via a user ID along with a
password-restricted log-in, and by encrypting the data they
entered. The questionnaire included questions concerning
gender, age, and underlying disease and its severity. The
severity of asthma was evaluated according to the criteria for
severity described in the ‘‘Guidelines for the Prevention and
Management of Asthma 2003’’5 and of COPD, according to the
British Medical Research Council (BMRC) Dyspnea Scale.10Statistical analysis
The answers obtained were tabulated separately for each
formulation, and the data were analyzed with stratification
by disease.
Using SPSS software, answers regarding adherence to
treatment, convenience, and willingness to replace drug
formulation were examined by the Mann–Whitney U-test,
and answers regarding reasons for poor adherence were
examined by Z-test, for comparisons of inhaled and
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Table 2 Respondents with usable answers by disease and drug used.
Frequency Total DPI-LABA MDI-SABA DPI-CS MDI-CS MDI-anticholinergic TP-LABA
Total 1470 523 567 279 132 42 470
Asthma Children 171 28 105 3 4 0 88
Adults 465 149 212 159 67 0 116
Elderly 411 124 174 117 61 0 154
COPDy Adults 241 123 51 0 0 31 55
Elderly 182 99 25 0 0 11 57
Children: patients aged 0–12 years (their patients answered the questionnaire). Adults: patients aged 18–64 years. Elderly: patients
over 65 years of age.
yCOPD patients include those diagnosed with chronic bronchitis or pulmonary emphysema.
Table 3 Attributes of respondents to the survey.
Number of patients Ratio (%)
Gender
Male 655 44.6
Female 815 55.4
Age
0–12 years 171 11.6
18–64 years 706 48.0
65 years or older 593 40.3
Range 1–76
Mean 47.8
Current disease
Asthma 1047 71.2
COPD 423 28.8
Severity of asthma in adults
Mild intermittent 508 58.0
Mild persistent 135 15.4
Moderate persistent 62 7.1
Severe persistent 171 19.5
Severity of asthma in children
Mild intermittent 96 56.1
Mild persistent 30 17.5
Moderate persistent 25 14.6
Severe persistent 1 1 0.6
Severe persistent 2 19 11.1
Severity of COPD
Grade 1 155 36.6
Grade 2 136 32.2
Grade 3 79 18.7
Grade 4 23 5.4
Grade 5 16 3.8
Grade 6 14 3.3
Adherence to therapy with inhaled and transdermal drugs 1897transdermal drugs. The level of statistical significance was
set at po0.05.
Results
Background factors of participants
Usable answers were obtained from 1470 respondents,
including 876 adult patients with asthma, parents of 171
asthmatic children, and 423 patients with COPD. Of these
respondents, 523 provided answers about DPI-LABA, 567
about MDI-SABA, 279 about DPI-CS, 132 about MDI-CS,
42 about MDI-anticholinergic, and 470 about TP-LABA
(Table 2).
Table 3 shows the characteristics of the patients who
provided useful answers. There were 655 males and 815
females, including 171 children aged 0–12 years, 706
patients aged 18–64 years, and 593 patients over 65 years
of age, and there were 1047 asthmatic and 423 COPD
patients. The most common levels of severity of asthma and
COPD as determined from the patients’ self-evaluation of
symptoms, were mild, intermittent asthma in 58.0% of adult
asthmatic patients, mild, intermittent asthma in 56.1% of
asthmatic children, and BMRC Dyspnea Scale Grade 1 COPD
in 36.6% of COPD patients.
Adherence to treatment
Comparison by drug formulation (Fig. 1)
Among asthmatic patients, the percentage of those who
selected ‘‘taking as prescribed’’ was 52.7% for inhalant users
and 83.2% for TP-LABA users . Among patients with COPD,
the corresponding percentages were 54.7% and 86.6%. The
difference in compliance between the inhalant and TP-LABA
users was significant in each group (po0.01).
Comparison of adherence to treatment according to the
agent and formulation prescribed (Fig. 2)
The percentage of users taking the drug as prescribed was
53.7% for DPI-LABA, 64.6% for MDI-SABA, 38.7% for DPI-CS,
39.4% for MDI-CS, 31.0% for MDI-anticholinergic, and 84.0%
for TP-LABA . The rates of adherence to treatment with DPI-
LABA and MDI-SABA were significantly higher than those to
DPI- and MDI-CS (po0.01), and the rate of adherence totreatment with MDI-SABA was significantly higher than that
to DPI-LABA (po0.01), though there was no difference in
rate between DPI- and MDI-CS. Rate of adherence was
significantly higher for TP-LABA than that to any of the
inhalants (po0.01).
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Figure 1 Adherence with regimens (asthmatic patients/COPD patients) by drug formulation. Q1. Are you taking drugs currently
prescribed for treatment of asthma/COPD as directed by your physicians? Please provide an answer for each drug.
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Figure 2 Adherence with regimens by indication. Q1. Are you taking drugs currently prescribed for treatment of asthma/COPD as
directed by your physicians? Please provide an answer for each drug.
G. Tamura, K. Ohta1898Factors influencing adherence to treatment
As shown in Fig. 3, for all users, the most common reason
for poor adherence among the four choices was ‘‘frequency
of administration’’. Although the percentage of users
of inhaled formulations who selected ‘‘frequency of
administration’’ was more than double that for each
of the other three reasons, the percentage of TP-LABA
users who selected ‘‘frequency of administration’’ and
‘‘timing of administration’’ was low, at 7.2% and 5.1%,
respectively. The percentage of TP-LABA users who selected‘‘frequency of administration’’ was significantly less than
those of the five inhalant users as determined by Z-test
(po0.01).Preferred frequency of administration
Fig. 4 shows the results for the question on preferred
frequency of administration; 83.2% of the patients preferred
the once-daily administration.
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Figure 3 Reasons for poor adherence. Q2. Which part of the treatment regimen is difficult to follow? Please provide an answer for
each drug (please select all that apply).
Three times a 
day or more 
0.9%
Twice a day 
15.8%
Once a day
83.2%
Figure 4 Preferred frequency of administration. Q3. Please
indicate the most preferable frequency of administration for
your asthma/COPD drugs.
Adherence to therapy with inhaled and transdermal drugs 1899Convenience of individual drugs
As shown in Fig. 5, among inhalant users, 42.7% of those with
asthma and 32.1% of COPD patients rated inhalants as ‘‘very
easy’’ to use, while 79.3% of patients with asthma and 73.2%
of those with COPD rated the patch as ‘‘very easy’’ to use.The difference in the percentage of inhalant and patch users
who answered ‘‘very easy’’ was significant in both groups
(po0.01).
Drug formulation (Fig. 6)
When patients who used or had used both inhalation and
transdermal formulations were asked whether they wished
to replace their inhalant with a transdermal drug, 18.0%
answered ‘‘definitely yes’’ and 37.7% answered ‘‘probably
yes’’, while 11.5% did not wish to switch, i.e., answered
‘‘definitely not’’ or ‘‘probably not’’ . When they were asked
whether they wished to switch the transdermal drug to
inhalants, 4.1% answered ‘‘definitely yes’’ and 9.4% an-
swered ‘‘probably yes’’, while 49.6% did not wish to switch.
The transdermal drug was undoubtedly preferred to inhalant
drugs (po0.01).
Discussion
In the present study, among patients with asthma and
COPD, more than 80% of TP-LABA users selected ‘‘taking
as prescribed’’, indicating higher rates of treatment
compliance compared with the inhaled drugs. These
findings suggest that TP-LABA, a drug featuring good
adherence to treatment for both types of airway diseases,
can be expected to be as effective in routine clinical
practice, as in carefully controlled clinical studies in
which patients are requested to take study drugs in
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4. Very easy
3. Easy 
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1. Difficult
4. Very easy
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Figure 5 Convenience of drugs (asthmatic patients/COPD patients). Q4. Please rate the convenience of use of your drugs for
asthma/COPD using the following rank scale.
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Figure 6 Willingness to replace drug formulation. The following questions are for patients who use or have used both inhaled drugs
and transdermal drug. Q5. Would you like to replace inhaled drugs with transdermal drug? Q6. Would you like to replace transdermal
drug with inhaled drugs?
G. Tamura, K. Ohta1900accordance with study protocols. In addition, at least
55% of patients who have used both inhaled drugs and
TP-LABA wished to switch from inhaled drugs to TP-LABA,
and many patients preferred transdermal to inhaled
formulations. We thus believe that TP-LABA is an ideallong-term controller which can be taken by patients
without fail. We therefore think that physicians should
consider TP-LABA to treat patients with asthma and
COPD, especially those with poor adherence to treatment
with inhaled drugs.
ARTICLE IN PRESS
Adherence to therapy with inhaled and transdermal drugs 1901The results of this survey are consistent with the low rate
of adherence to treatment with inhaled drugs pointed out by
physicians.1–4,11,12 Some of them have reported that this low
rate appears to be due to the need for special instructions to
ensure appropriate inhalation and the complicated proce-
dures required for inhalation.1,13 However, we suggest that
special and complicated instructions are not the only
important reasons for poor adherence, since we found that
the most commonly selected reason for poor adherence was
‘‘frequency of administration’’, and since the rates of
adherence to treatment with DPI-LABA and MDI-SABA were
significantly higher than those for DPI- and MDI-CS. Our
finding of a good rate of adherence to treatment with TP-
LABA appears to be related to its once-daily application and
ease of use.
As shown in Table 3, more than half of the respondents
with asthma had mild, intermittent asthma, and about 70%
of those with COPD had Grade 1 or 2 COPD. Since the
participants were randomly selected from among asthmatic
patients who had been under treatment with DPI-LABA, MDI-
SABA, DPI-CS, MDI-CS, or TP-LABA and COPD patients
treated with DPI-LABA, MDI-SABA, MDI-anticholinergic, or
TP-LABA, all the patients evaluated in this survey were
regularly receiving drugs for airway disease. The fact that
some patients who reported having mild, intermittent
asthma received MDI-SABA together with DPI-LABA, DPI-CS,
MDI-CS, or TP-LABA suggests that patients reported the
severity of their disease on the basis of symptoms during
drug treatment, which may have resulted in underestima-
tion of true disease severity. Given that the severity of their
condition would be severer if evaluated before treatment
for the actual severity, and that certain patients control
their condition with bronchodilators alone, more asthmatic
participants should be treated with inhaled corticosteroids.
But the participants in this survey may be more conscious of
their disease than are average patients in Japan, since
Adachi et al.14 have reported that 18% of adults and 8% of
children with asthma used inhaled corticosteroids in Japan.
This survey may also reveal a discrepancy, which needs to be
addressed, between the guidelines for treatment and the
fashion in which patients are actually treated in clinical
practice.
For this survey, we selected an Internet-based question-
naire to evaluate the actual use of transdermal and inhaled
drugs by patients with either asthma or COPD. We thought
that an Internet-based questionnaire would have certain
advantages in evaluating adherence to treatment with
various drugs, since it is useful in eliminating biases resulting
from false reports by patients who may wish their attending
physician to regard them as good patients by virtue of
maintaining their dosing schedules. The results of our
Internet-based survey may thus reflect treatment adherence
in clinical practice, unlike those obtained in carefully
controlled trials. Usage of the Internet was reported to be
correlated with household income in ‘‘A survey on use of
communication services in Japan’’ (http://www.stat.go.jp/
data/joukyou/2003ni/index.htm) conducted by the Ministry
of Internal Affairs and Communications of Japan. Since it has
also been reported that adherence to treatment is higher in
case of patients with higher household income,15,16 partici-
pants in the present survey may show better treatment
compliance than do average patients in Japan. In addition,patients with better adherence may have responded to this
survey faster than those with poor adherence to treatment.
These considerations suggest that in clinical practice,
treatment compliance may be lower than suggested by the
results of this survey.
In summary, to obtain in clinical practice the same degree
of efficacy as in carefully controlled trials, health care
professionals should improve adherence to treatment with
inhaled drugs by further educating their patients about the
importance of inhaled agents. In addition, inhalant users
selected the ‘‘frequency of administration’’ as the primary
reason for their poor adherence, which suggests the reason
why adherence in once-daily TP-LABA users was the highest.
Therefore, TP-LABA appears to be useful for long-term
control of asthma and COPD.References
1. Kelloway JS, Wyatt RA, Adlis SA. Comparison of patients’
compliance with prescribed oral and inhaled asthma medica-
tions. Arch Intern Med 1994;154:1349–52.
2. Jones C, Santanello NC, Boccuzzi SJ, Wogen J, Strub P, Nelsen
LM. Adherence to prescribed treatment for asthma: evidence
from pharmacy benefits data. J Asthma 2003;40:93–101.
3. Cochrane MG, Bala MV, Downs KE, Mauskopf J, Ben-Joseph RH.
Inhaled corticosteroids for asthma therapy: patient compliance,
devices, and inhalation technique. Chest 2000;117:542–50.
4. Hyland ME. Rationale for once-daily therapy in asthma:
compliance issues. Drugs 1999;58:1–6.
5. Makino S, Furusho K, Miyamoto T, et al. The guidelines for the
prevention and management of asthma 2003. Tokyo: Kyowa
Kikaku; 2003. p. 1–194 [in Japanese].
6. Miyamoto T, editor. The Ministry of Health, Labor, and Welfare
Medical Practice Evaluation Study Group Asthma Guideline
Unit: the EBM-based guidelines for the treatment of asthma.
Tokyo: Kyowa Kikaku; 2001 [in Japanese].
7. The Japanese Respiratory Society COPD Guideline Preparation
Committee. The Japanese Respiratory Society COPD Guide-
lines—guidelines for the diagnosis and treatment of chronic
obstructive pulmonary disease (COPD). Tokyo: Medical Review
Sha; 1999 [in Japanese].
8. Tamura G, Sano Y, Hirata K, Ishioka S, Nakashima M, Miyamoto T.
Effect of transdermal tulobuterol added to inhaled corticoster-
oids in asthma patients. Allergol Int 2005;54:615–20.
9. Fukuchi Y, Nagai A, Seyama K, et al. Clinical efficacy and safety
of transdermal tulobuterol in the treatment of stable COPD: an
open-label comparison with inhaled salmeterol. Treat Respir
Med 2005;4:447–55.
10. Brooks SM. Surveillance for respiratory hazards. ATS News
1982;8:12–6.
11. Milgrom H, Bender B, Ackerson L, Bowry P, Smith B, Rand C.
Noncompliance and treatment failure in children with asthma.
J Allergy Clin Immunol 1996;98:1051–7.
12. Bukstein DA, Bratton DL, Firriolo KM, et al. Evaluation of
parental preference for the treatment of asthmatic children
aged 6 to 11 years with oral montelukast or inhaled cromolyn: a
randomized, open-label, crossover study. J Asthma 2003;40:
475–85.
13. Welch MJ, Nelson HS, Shapiro G, et al. Comparison of patient
preference and ease of teaching inhaler technique for
Pulmicort Turbuhaler versus pressurized metered-dose inhalers.
J Aerosol Med 2004;17:129–39.
14. Adachi M, Ohta K, Morikawa A, Nishima S. Asthma insights
and reality in Japan 2005. Jpn J Allergol 2006;55:1340–3
[in Japanese].
ARTICLE IN PRESS
G. Tamura, K. Ohta190215. Apter AJ, Reisine ST, Affleck G, Barrows E, ZuWallack RL.
Adherence with twice-daily dosing of inhaled steroids. Socio-
economic and health-belief differences. Am J Respir Crit Care
Med 1998;157:1810–7.16. Apter AJ, Boston RC, George M, Norfleet AL, Tenhave T, Coyne
JC, et al. Modifiable barriers to adherence to inhaled steroids
among adults with asthma: it’s not just black and white.
J Allergy Clin Immunol 2003;111:1219–26.
